<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    11110735
   </pmid>
   <datecreated>
    <year>
     2000
    </year>
    <month>
     12
    </month>
    <day>
     29
    </day>
   </datecreated>
   <datecompleted>
    <year>
     2001
    </year>
    <month>
     02
    </month>
    <day>
     15
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2009
    </year>
    <month>
     11
    </month>
    <day>
     18
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Print">
      0959-8138
     </issn>
     <journalissue citedmedium="Print">
      <volume>
       321
      </volume>
      <issue>
       7274
      </issue>
      <pubdate>
       <year>
        2000
       </year>
       <month>
        Dec
       </month>
       <day>
        9
       </day>
      </pubdate>
     </journalissue>
     <title>
      BMJ (Clinical research ed.)
     </title>
     <isoabbreviation>
      BMJ
     </isoabbreviation>
    </journal>
    <articletitle>
     Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study.
    </articletitle>
    <pagination>
     <medlinepgn>
      1440-4
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext label="OBJECTIVES" nlmcategory="OBJECTIVE">
      To assess and compare the effects of candesartan or lisinopril, or both, on blood pressure and urinary albumin excretion in patients with microalbuminuria, hypertension, and type 2 diabetes.
     </abstracttext>
     <abstracttext label="DESIGN" nlmcategory="METHODS">
      Prospective, randomised, parallel group, double blind study with four week placebo run in period and 12 weeks' monotherapy with candesartan or lisinopril followed by 12 weeks' monotherapy or combination treatment.
     </abstracttext>
     <abstracttext label="SETTING" nlmcategory="METHODS">
      Tertiary hospitals and primary care centres in four countries (37 centres).
     </abstracttext>
     <abstracttext label="PARTICIPANTS" nlmcategory="METHODS">
      199 patients aged 30-75 years.
     </abstracttext>
     <abstracttext label="INTERVENTIONS" nlmcategory="METHODS">
      Candesartan 16 mg once daily, lisinopril 20 mg once daily.
     </abstracttext>
     <abstracttext label="MAIN OUTCOME MEASURES" nlmcategory="METHODS">
      Blood pressure and urinary albumin:creatinine ratio.
     </abstracttext>
     <abstracttext label="RESULTS" nlmcategory="RESULTS">
      At 12 weeks mean (95% confidence interval) reductions in diastolic blood pressure were 9.5 mm Hg (7.7 mm Hg to 11.2 mm Hg, P&lt;0.001) and 9.7 mm Hg (7.9 mm Hg to 11.5 mm Hg, P&lt;0.001), respectively, and in urinary albumin:creatinine ratio were 30% (15% to 42%, P&lt;0.001) and 46% (35% to 56%, P&lt;0.001) for candesartan and lisinopril, respectively. At 24 weeks the mean reduction in diastolic blood pressure with combination treatment (16.3 mm Hg, 13.6 mm Hg to 18.9 mm Hg, P&lt;0. 001) was significantly greater than that with candesartan (10.4 mm Hg, 7.7 mm Hg to 13.1 mm Hg, P&lt;0.001) or lisinopril (mean 10.7 mm Hg, 8.0 mm Hg to 13.5 mm Hg, P&lt;0.001). Furthermore, the reduction in urinary albumin:creatinine ratio with combination treatment (50%, 36% to 61%, P&lt;0.001) was greater than with candesartan (24%, 0% to 43%, P=0.05) and lisinopril (39%, 20% to 54%, P&lt;0.001). All treatments were generally well tolerated.
     </abstracttext>
     <abstracttext label="CONCLUSION" nlmcategory="CONCLUSIONS">
      Candesartan 16 mg once daily is as effective as lisinopril 20 mg once daily in reducing blood pressure and microalbuminuria in hypertensive patients with type 2 diabetes. Combination treatment is well tolerated and more effective in reducing blood pressure.
     </abstracttext>
    </abstract>
    <affiliation>
     Department of Medicine, M, Kommunehospitalet, University Hospital, DK-8000 Aarhus C, Denmark. cem@afdm.au.dk
    </affiliation>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       Mogensen
      </lastname>
      <forename>
       C E
      </forename>
      <initials>
       CE
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Neldam
      </lastname>
      <forename>
       S
      </forename>
      <initials>
       S
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Tikkanen
      </lastname>
      <forename>
       I
      </forename>
      <initials>
       I
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Oren
      </lastname>
      <forename>
       S
      </forename>
      <initials>
       S
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Viskoper
      </lastname>
      <forename>
       R
      </forename>
      <initials>
       R
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Watts
      </lastname>
      <forename>
       R W
      </forename>
      <initials>
       RW
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Cooper
      </lastname>
      <forename>
       M E
      </forename>
      <initials>
       ME
      </initials>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <publicationtypelist>
     <publicationtype>
      Clinical Trial
     </publicationtype>
     <publicationtype>
      Comparative Study
     </publicationtype>
     <publicationtype>
      Journal Article
     </publicationtype>
     <publicationtype>
      Multicenter Study
     </publicationtype>
     <publicationtype>
      Randomized Controlled Trial
     </publicationtype>
     <publicationtype>
      Research Support, Non-U.S. Gov't
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     ENGLAND
    </country>
    <medlineta>
     BMJ
    </medlineta>
    <nlmuniqueid>
     8900488
    </nlmuniqueid>
    <issnlinking>
     0959-535X
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Angiotensin-Converting Enzyme Inhibitors
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Antihypertensive Agents
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Benzimidazoles
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Tetrazoles
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      139481-59-7
     </registrynumber>
     <nameofsubstance>
      candesartan
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      83915-83-7
     </registrynumber>
     <nameofsubstance>
      Lisinopril
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    AIM
   </citationsubset>
   <citationsubset>
    IM
   </citationsubset>
   <commentscorrectionslist>
    <commentscorrections reftype="Cites">
     <refsource>
      Circulation. 1999 Mar 2;99(8):990-2
     </refsource>
     <pmid version="1">
      10051289
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      J Hypertens. 1999 Feb;17(2):151-83
     </refsource>
     <pmid version="1">
      10067786
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      J Intern Med. 1999 Feb;245(2):111-26
     </refsource>
     <pmid version="1">
      10081514
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Am J Nephrol. 1999;19(1):1-6
     </refsource>
     <pmid version="1">
      10085442
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Am J Kidney Dis. 1999 May;33(5):851-6
     </refsource>
     <pmid version="1">
      10213639
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      BMJ. 1999 Jul 3;319(7201):24-5
     </refsource>
     <pmid version="1">
      10390455
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      BMJ. 1999 Sep 4;319(7210):630-5
     </refsource>
     <pmid version="1">
      10473485
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Lancet. 2000 Jan 22;355(9200):253-9
     </refsource>
     <pmid version="1">
      10675071
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      J Hypertens. 2000 Jan;18(1):89-95
     </refsource>
     <pmid version="1">
      10678548
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Lancet. 1995 Nov 25;346(8987):1403-7
     </refsource>
     <pmid version="1">
      7475826
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Lancet. 1995 Oct 21;346(8982):1080-4
     </refsource>
     <pmid version="1">
      7564792
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Circulation. 1995 Aug 15;92(4):825-34
     </refsource>
     <pmid version="1">
      7641363
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Am J Physiol. 1995 Apr;268(4 Pt 2):F588-94
     </refsource>
     <pmid version="1">
      7733315
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Circulation. 1995 Mar 15;91(6):1655-8
     </refsource>
     <pmid version="1">
      7882471
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      J Hum Hypertens. 1996 Mar;10(3):185-92
     </refsource>
     <pmid version="1">
      8733038
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      JAMA. 1996 Aug 28;276(8):637-9
     </refsource>
     <pmid version="1">
      8773637
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Clin Sci (Lond). 1996 Mar;90(3):205-13
     </refsource>
     <pmid version="1">
      8777826
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      BMJ. 1996 Sep 7;313(7057):591-4
     </refsource>
     <pmid version="1">
      8806248
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Hypertension. 1997 Feb;29(2):634-40
     </refsource>
     <pmid version="1">
      9040450
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      J Clin Invest. 1997 Apr 1;99(7):1585-95
     </refsource>
     <pmid version="1">
      9120002
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Drugs. 1997 Jun;53(6):1081-105
     </refsource>
     <pmid version="1">
      9179532
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Lancet. 1997 Jun 21;349(9068):1787-92
     </refsource>
     <pmid version="1">
      9269212
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Diabetes. 1997 Oct;46(10):1612-8
     </refsource>
     <pmid version="1">
      9313758
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Arch Intern Med. 1997 Nov 24;157(21):2413-46
     </refsource>
     <pmid version="1">
      9385294
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Lancet. 1998 Jan 3;351(9095):28-31
     </refsource>
     <pmid version="1">
      9433426
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Lancet. 1998 Jul 18;352(9123):213-9
     </refsource>
     <pmid version="1">
      9683226
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Hypertension. 1998 Sep;32(3):387-92
     </refsource>
     <pmid version="1">
      9740600
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      J Hypertens. 1998 Jul;16(7):1023-9
     </refsource>
     <pmid version="1">
      9794744
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Drugs. 1998 Nov;56(5):847-69
     </refsource>
     <pmid version="1">
      9829158
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="CommentIn">
     <refsource>
      BMJ. 2001 May 12;322(7295):1183
     </refsource>
     <pmid version="1">
      11379586
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="CommentIn">
     <refsource>
      ACP J Club. 2001 Jul-Aug;135(1):9
     </refsource>
    </commentscorrections>
   </commentscorrectionslist>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Adult
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Aged
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Albuminuria
     </descriptorname>
     <qualifiername majortopicyn="Y">
      drug therapy
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Angiotensin-Converting Enzyme Inhibitors
     </descriptorname>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Antihypertensive Agents
     </descriptorname>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Benzimidazoles
     </descriptorname>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Diabetes Mellitus, Type 2
     </descriptorname>
     <qualifiername majortopicyn="Y">
      drug therapy
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Hypertension
     </descriptorname>
     <qualifiername majortopicyn="Y">
      drug therapy
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Lisinopril
     </descriptorname>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Middle Aged
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Prospective Studies
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Renin-Angiotensin System
     </descriptorname>
     <qualifiername majortopicyn="Y">
      drug effects
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Tetrazoles
     </descriptorname>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Treatment Outcome
     </descriptorname>
    </meshheading>
   </meshheadinglist>
   <otherid source="NLM">
    PMC27545
   </otherid>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      2000
     </year>
     <month>
      12
     </month>
     <day>
      9
     </day>
     <hour>
      11
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      2001
     </year>
     <month>
      3
     </month>
     <day>
      3
     </day>
     <hour>
      10
     </hour>
     <minute>
      1
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      2000
     </year>
     <month>
      12
     </month>
     <day>
      9
     </day>
     <hour>
      11
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pubmed">
     11110735
    </articleid>
    <articleid idtype="pmc">
     PMC27545
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

